Is GC Biopharma profitable in 2026?

GC Biopharma returned to profit in Q4 2025, its first profitable fourth quarter in seven years, with FY2025 operating profit of 69.1 billion KRW, more than double 2024's figure, on 18.5% revenue growth to about 1.9913 trillion KRW, per a January 27, 2026 report.

What is driving GC Biopharma's revenue growth?

Alyglo, GC's US IVIG product launched September 9, 2024, grew every quarter in 2025 and rose 117% year over year in Q3 2025, pushing full-year 2025 US Alyglo sales above 150 billion KRW (about $106M), per company reporting cited January 27, 2026.

Who owns GC Biopharma?

GC Biopharma is majority controlled by GC Corp, the Huh family's holding company, which held roughly 51.26% of shares as of September 30, 2025, keeping strategic control concentrated in the founding family rather than dispersed public shareholders.

Could AI replace GC Biopharma's business?

No. GC's core value is FDA-licensed plasma manufacturing and about 8 US plasma centers collecting roughly 400,000 liters per year, physical and regulatory assets AI cannot replicate; GC's AI use is limited to a May 2026 government-funded drug discovery validation role.

How big is the Curevo sale to Eli Lilly for GC Biopharma?

GC Biopharma sold its 20.3% Curevo stake to Eli Lilly for about 459.9 billion KRW ($303.9M) announced May 27, 2026, receiving a first tranche of $189.52M on July 9, 2026, while retaining a manufacturing supply deal and future royalty rights.

Who is GC Biopharma's biggest competitor?

GC Biopharma competes against CSL Behring, Grifols, Takeda, Octapharma, and Kedrion, which together hold an estimated 75-80% of the global plasma-fractionation market as of a July 31, 2025 industry report, making GC a smaller, faster-growing challenger rather than a leader.

Biotech tools companies · subsidiary of GC Corp (holding company); note: GC Biopharma is publicly listed on KRX (006280) but GC Corp holds 51.26% controlling stake · South Korea

GC Biopharma

gcbiopharma.com ↗

Korean maker of plasma-derived drugs like IVIG and vaccines, formerly Green Cross.

Hard to displace

Assessed 30 July 2026 · Evidence as of 30 July 2026

Strong structural protection; the business model survives ai pressure.

On the recordSince 30 July 2026 · Checkable from Q3 2026 · Every call on the record Checkpoint: Q2/Q3 2026 earnings, which show whether the profit turnaround holds once Curevo cash stops landing

The call

GC Biopharma just posted its first profitable Q4 in seven years, riding Alyglo's US growth and a one-time Curevo payout, in a plasma market the big five fractionators still dominate.

GC Biopharma makes medicines from donated blood plasma, a business that requires FDA permission, physical collection centers, and years of government approval to operate. Competitors like CSL and Grifols control most of the market and have built-in advantages that AI and new companies cannot quickly copy, because you cannot get an FDA license overnight or build a plasma network from scratch. The real question is whether GC's recent profit jump comes from genuine growth in its US product or just from a one-time cash infusion from selling a business unit to Eli Lilly; if it is the latter, profits may disappear in 2026 and 2027, and family ownership means most shareholders will never see big returns.

Why

AI pressure: None apparent. Plasma collection, fractionation, and FDA biologics licensing are physical and regulatory work AI does not touch. Could AI do the core job? Unlikely.

Bigger players: CSL Behring, Grifols, Takeda, Octapharma, Kedrion. These five already hold 75-80% of global plasma fractionation, competing directly against GC's Alyglo in IVIG. Could a giant copy it? No, they are blocked.

What protects it. FDA licensure plus its own US plasma centers and collection volume, things a new entrant cannot stand up quickly.

What would change this call

Q2/Q3 2026 operating profit results once Curevo cash inflows taper off. Shows whether the 2025 turnaround was organic (Alyglo/margins) or a one-time cash effect.
Escalation of the May 2026 FDA warning letter to GC America into a wider compliance action. Would signal manufacturing risk to Alyglo supply and US revenue.
Korea Constitutional Court ruling on the vaccine bid-rigging antitrust appeal. Would show whether GC Biopharma faces procurement bans or added legal costs in Korea.

Key numbers

FY2025 revenue 1.9913T KRW, up 18.5% YoY, a record (2026-01-27)
Alyglo US sales topped 150B KRW (~$106M) in 2025 (2026-01-27)
Curevo stake sold to Eli Lilly for ~459.9B KRW (~$304M) (2026-05-27)

Named risks

FY2025 profit turnaround may depend on one-time Curevo cash rather than organic operations. Severity: high
FDA warning letter to GC America (May 2026) could escalate into broader manufacturing compliance action. Severity: medium
Constitutional Court antitrust appeal outcome could impose further penalties or reputational damage. Severity: medium
Family control via GC Corp (51.26%) limits minority shareholder influence and upside. Severity: low
Structural subscale position behind CSL, Grifols, Takeda caps long-term market share gains. Severity: medium

Rivals, as read in July 2026

Rival	Direction	Evidence
CSL Behring	losing to	CSL among five firms holding 75-80% of global plasma-fractionation share as of 2025-07-31
Grifols	losing to	Named alongside CSL as dominant plasma player controlling most of global market share, 2025
Takeda	losing to	Part of the five-firm oligopoly holding 75-80% global plasma share, 2025-07-31
Eli Lilly	contesting	Acquired GC's Curevo affiliate for $1.5B in shingles vaccine deal, announced 2026-05-27
Teleflex/Vascular Solutions	gaining on	FDA licensed rival freeze-dried plasma product Ezplaz on 2026-07-29, new adjacent competitor

Questions people ask

Is GC Biopharma profitable in 2026?: GC Biopharma returned to profit in Q4 2025, its first profitable fourth quarter in seven years, with FY2025 operating profit of 69.1 billion KRW, more than double 2024's figure, on 18.5% revenue growth to about 1.9913 trillion KRW, per a January 27, 2026 report.
What is driving GC Biopharma's revenue growth?: Alyglo, GC's US IVIG product launched September 9, 2024, grew every quarter in 2025 and rose 117% year over year in Q3 2025, pushing full-year 2025 US Alyglo sales above 150 billion KRW (about $106M), per company reporting cited January 27, 2026.
Who owns GC Biopharma?: GC Biopharma is majority controlled by GC Corp, the Huh family's holding company, which held roughly 51.26% of shares as of September 30, 2025, keeping strategic control concentrated in the founding family rather than dispersed public shareholders.
Could AI replace GC Biopharma's business?: No. GC's core value is FDA-licensed plasma manufacturing and about 8 US plasma centers collecting roughly 400,000 liters per year, physical and regulatory assets AI cannot replicate; GC's AI use is limited to a May 2026 government-funded drug discovery validation role.
How big is the Curevo sale to Eli Lilly for GC Biopharma?: GC Biopharma sold its 20.3% Curevo stake to Eli Lilly for about 459.9 billion KRW ($303.9M) announced May 27, 2026, receiving a first tranche of $189.52M on July 9, 2026, while retaining a manufacturing supply deal and future royalty rights.
Who is GC Biopharma's biggest competitor?: GC Biopharma competes against CSL Behring, Grifols, Takeda, Octapharma, and Kedrion, which together hold an estimated 75-80% of the global plasma-fractionation market as of a July 31, 2025 industry report, making GC a smaller, faster-growing challenger rather than a leader.

Timeline

2026-07-09GC receives first Curevo sale tranche of $189.52M from Eli Lilly
2026-06-24Q1 2026 revenue reported at 435.53B KRW, up 13.49% year over year
2026-05-27GC sells 20.3% Curevo stake to Eli Lilly for about $303.9M
2026-05-15GC joins government-backed AI drug discovery platform project
2026-05-14FDA issues warning letter to GC America over CGMP deficiencies
2026-04-29Constitutional Court accepts GC's antitrust penalty appeal
2026-02-01Korea Supreme Court upholds 2.035B KRW antitrust penalty on GC
2026-01-27GC reports FY2025 revenue of 1.9913T KRW, up 18.5% year over year
2025-11-03Q3 2025 sales hit record 609.5B KRW, up 31% year over year
2024-09-09Alyglo commercial launch begins in the US market

Revision history

30 July 2026

First assessed. Hard to displace. The text above is fixed as of this date and is not edited afterwards.

In the same band

Merck KGaA (MilliporeSigma)Intertek Group plc Eurofins Scientific SE